NCT05901545 2026-03-05
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
Clinical Trials
11 trialsNCT05747625 2025-12-19
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
NCT05423197 2025-07-16
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
Stanford University
Phase 2 Not yet recruiting
NCT03733210 2023-05-19
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Stanford University
Phase 1 Completed
NCT02643056 2021-10-27
S10PANI01
Southern Europe New Drug Organization
Phase 2 Completed
NCT01264328 2019-04-16
VECTITAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Completed
NCT00798655 2017-10-03
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00513383 2017-03-01
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Massachusetts General Hospital
Phase 1 Completed
NCT01634880 2016-05-23
Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT01312493 2015-08-28
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01305772 2014-08-29
TOP0901
Duke University
Phase 2 Terminated